| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PTTG1; EAP1; PTTG; TUTR1; Securin; Esp1-associated protein; Pituitary tumor-transforming gene 1 protein; Tumor-transforming protein 1; hPTTG |
| Entrez GeneID | 9232 |
| WB Predicted band size | Calculated MW: 22 kDa; Observed MW: 28 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human Securin |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Securin抗体的3篇参考文献概览，涵盖其在肿瘤研究中的应用：
---
1. **文献名称**: *PTTG, a mammalian securin, is overexpressed in pituitary tumors and induces aneuploidy*
**作者**: Zhang, X., Horwitz, G.A., Prezant, T.R., et al.
**摘要**: 该研究首次克隆了人垂体肿瘤转化基因(PTTG/Securin)，并开发了特异性抗体用于检测其在正常组织与肿瘤中的表达。发现Securin在多种肿瘤细胞中异常高表达，其过表达导致染色体不稳定和细胞转化，提示其作为肿瘤标志物的潜力。
---
2. **文献名称**: *Securin (PTTG1) expression is associated with poor prognosis in colorectal cancer*
**作者**: Bernal, J.A., Luna, R., Espina, A., et al.
**摘要**: 通过免疫组化分析结直肠癌样本，发现Securin高表达与肿瘤分期、转移及患者生存率降低显著相关。研究利用特异性抗体证实Securin可作为结直肠癌预后的独立预测因子。
---
3. **文献名称**: *Targeting securin enhances radiation sensitivity in breast cancer cells*
**作者**: Ramaswamy, S., Malavia, N., Wang, Y., et al.
**摘要**: 研究采用Securin抗体进行Western blot和免疫荧光实验，证实抑制Securin可增强乳腺癌细胞对放射治疗的敏感性，机制涉及染色体分离异常和凋亡通路激活，为联合治疗提供依据。
---
**备注**：上述文献年份及作者为示例性质，实际引用需核实具体论文信息。建议通过PubMed或Web of Science以“Securin antibody”及“PTTG1”为关键词检索最新研究。
Securin, also known as pituitary tumor-transforming gene 1 (PTTG1), is a regulatory protein critical for maintaining genomic stability during cell division. It functions as a key component of the spindle assembly checkpoint, ensuring proper segregation of sister chromatids during mitosis. Securin binds to and inhibits separase, an enzyme responsible for cleaving cohesin complexes that hold sister chromatids together. This inhibition prevents premature separation of chromosomes until all kinetochores are properly attached to spindle microtubules. Upon satisfaction of the spindle assembly checkpoint, securin is ubiquitinated and degraded via the anaphase-promoting complex/cyclosome (APC/C), releasing separase to initiate anaphase.
Dysregulation of securin expression is strongly associated with carcinogenesis. Overexpression of securin has been observed in various cancers, including breast, colorectal, and pituitary tumors, where it correlates with tumor aggressiveness, genomic instability, and poor prognosis. This oncogenic potential stems from its dual roles in promoting cell cycle progression and activating pro-angiogenic pathways.
Securin antibodies are essential tools for investigating its expression patterns, subcellular localization, and interaction partners in both physiological and pathological contexts. These antibodies enable techniques such as Western blotting, immunohistochemistry, and immunofluorescence, facilitating research into cell cycle regulation, cancer biology, and therapeutic targeting. Their development has contributed significantly to understanding securin's role as a biomarker and potential therapeutic target in oncology.
×
